Terns Pharmaceuticals (TERN) Price & Analysis

Compare

425 Followers

TERN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.87 - $11.40

Previous CloseN/A

Volume294.76K

Average Volume (3M)1.13M

Market Cap

$573.20M

Enterprise Value$27.26M

Total Cash (Recent Filing)$315.44M

Total Debt (Recent Filing)$1.13M

Price to Earnings (P/E)―

Beta1.87

Next Earnings

Nov 18, 2025

EPS Estimate

-0.3

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding87,511,050

10 Day Avg. Volume1,298,922

30 Day Avg. Volume1,128,269

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.05

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-252.43

Enterprise Value/Ebitda-0.27

Forecast

1Y Price Target

$17.00

Price Target Upside169.84% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Financial HealthTERN ended the quarter with $334.5M in cash, providing an operational expenditure runway into 2028.

Market PositioningPrimary care practitioners are expected to favor prescribing oral medications over injectables, which could lead to high adoption rates of Terns Pharmaceuticals' oral GLP-1 candidate.

Product DifferentiationTERN-601 could be a game changer if key data shows TERN's oral GLP-1 to be differentiated, particularly on tolerability.

Bears Say

Competitive LandscapeQuestions may emerge on the competitive profiles of oral GLP-1's versus injectable GLP-1's and their potential positioning in the market.

Differentiation ChallengesA differentiation thesis is not clear at the moment, given the increasing competitiveness of both the CML and obesity treatment landscape.

Financial PerformanceTerns Pharmaceuticals reported a net loss of $24.1M in 2Q25.

Terns Pharmaceuticals News

Disappointing competitor oral GLP-1 data an opportunity for Terns, says Mizuho

After Viking Therapeutics (VKTX) yesterday announced 13-week Phase 2 data for VK2735, an oral GIP/GLP-1-based candidate for obesity,...

2d ago

LLY

TERN

Terns Pharmaceuticals reports Q2 EPS (26c), consensus (29c)

As of June 30, 2025, cash, cash equivalents and marketable securities were $315.4M, as compared with $358.2M as...

17d ago

TERN

Terns Pharmaceuticals: A Promising Buy Amid Competitor Challenges in the Oral GLP-1 Space

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on TERN stock, giving a Buy rating on...

2d ago

TERN

Terns Pharmaceuticals Reports Q2 2025 Financial Results

Terns Pharmaceuticals, Inc. ( ($TERN) ) has released its Q2 earnings. Here is a breakdown of the information...

17d ago

TERN

Terns Pharmaceuticals initiated with Early-Stage Biotech at Goldman Sachs

Goldman Sachs analyst Corinne Johnson started Terns Pharmaceuticals (TERN) with an Early-Stage Biotech rating. Published first on TheFly...

1M ago

TERN

Terns Pharmaceuticals Approves Directors and Accounting Firm

The latest update is out from Terns Pharmaceuticals ( ($TERN) ). On June 11, 2025, Terns Pharmaceuticals held...

2M ago

TERN

Terns Pharmaceuticals price target lowered to $15 from $26 at BMO Capital

BMO Capital lowered the firm’s price target on Terns Pharmaceuticals (TERN) to $15 from $26 and keeps an...

3M ago

PFE

TERN

Terns Pharmaceuticals Reports Q1 2025 Financial Results

Terns Pharmaceuticals, Inc. ( ($TERN) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

TERN

Promising Potential and Financial Stability Drive Buy Rating for Terns Pharmaceuticals

Terns Pharmaceuticals (TERN) has received a new Buy rating, initiated by TD Cowen analyst, Ritu Baral. Ritu Baral...

3M ago

TERN

Terns Pharmaceuticals reports Q1 EPS (26c), consensus (27c)

“Terns had a strong start to 2025, marked by continued excellent execution on our two lead clinical programs....

4M ago

TERN

Terns Pharmaceuticals files $300M mixed securities shelf

16:45 EDT Terns Pharmaceuticals (TERN) files $300M mixed securities shelf Published first on TheFly – the ultimate source...

4M ago

TERN

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

DYN

ANVS

Terns Pharmaceuticals management to meet with Oppenheimer

Meeting to be held in Fairfield, CT on April 14 and in New York on April 15 hosted...

5M ago

TERN

Promising Clinical Trials and Strong Financials Drive Buy Rating for Terns Pharmaceuticals

TD Cowen analyst Ritu Baral has maintained their bullish stance on TERN stock, giving a Buy rating on...

5M ago

TERN

TERN FAQ

What was Terns Pharmaceuticals’s price range in the past 12 months?

Terns Pharmaceuticals lowest stock price was $1.86 and its highest was $11.40 in the past 12 months.

What is Terns Pharmaceuticals’s market cap?

Terns Pharmaceuticals’s market cap is $573.20M.

When is Terns Pharmaceuticals’s upcoming earnings report date?

Terns Pharmaceuticals’s upcoming earnings report date is Nov 18, 2025 which is in 88 days.

How were Terns Pharmaceuticals’s earnings last quarter?

Terns Pharmaceuticals released its earnings results on Aug 05, 2025. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.03.

Is Terns Pharmaceuticals overvalued?

According to Wall Street analysts Terns Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Terns Pharmaceuticals pay dividends?

Terns Pharmaceuticals does not currently pay dividends.

What is Terns Pharmaceuticals’s EPS estimate?

Terns Pharmaceuticals’s EPS estimate is -0.3.

How many shares outstanding does Terns Pharmaceuticals have?

Terns Pharmaceuticals has 87,511,050 shares outstanding.

What happened to Terns Pharmaceuticals’s price movement after its last earnings report?

Terns Pharmaceuticals reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went down -6.743%.

Which hedge fund is a major shareholder of Terns Pharmaceuticals?

Currently, no hedge funds are holding shares in TERN

Terns Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-35.02%

Trailing 12-Months

Asset Growth

38.78%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Terns Pharmaceuticals

Terns Pharmaceuticals (TERN) is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for the treatment of liver diseases and cancer. The company focuses on addressing significant unmet medical needs by advancing a robust pipeline of small-molecule therapeutics. Terns Pharmaceuticals operates within the healthcare sector, specifically targeting conditions such as non-alcoholic steatohepatitis (NASH) and other liver-related diseases, utilizing its expertise in drug discovery and development.

Terns Pharmaceuticals (TERN) Earnings & Revenues

Historic Earnings Reports

TERN Stock 12 Month Forecast

Average Price Target

$17.00

▲(169.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","16":"$16","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6,11,16,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.47,6.587692307692308,7.705384615384615,8.823076923076922,9.94076923076923,11.05846153846154,12.176153846153845,13.293846153846154,14.411538461538463,15.529230769230768,16.646923076923077,17.764615384615386,18.88230769230769,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.47,6.356923076923077,7.243846153846154,8.13076923076923,9.017692307692307,9.904615384615385,10.791538461538462,11.678461538461539,12.565384615384616,13.452307692307693,14.33923076923077,15.226153846153846,16.113076923076925,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.47,6.126153846153846,6.782307692307692,7.438461538461539,8.094615384615384,8.750769230769231,9.406923076923077,10.063076923076924,10.71923076923077,11.375384615384615,12.031538461538462,12.68769230769231,13.343846153846155,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.77,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.62,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >